The inherited retinal disease (IRD) community is keenly awaiting new developments in vision restoration, and Nanoscope Therapeutics is set to share significant findings at the 28th annual meeting of the American Society of Gene and Cell Therapy (ASGCT 2025). This event, a key gathering for gene and cell therapy professionals, will provide a platform for Nanoscope to present their latest research on optogenetic therapies, offering a beacon of hope for individuals living with IRDs.
Nanoscope Therapeutics, a biotech company focused on restoring vision, announced on May 12, 2025, that it will deliver multiple presentations at ASGCT 2025. The meeting is scheduled to take place from May 13-17, 2025, at the Ernest N. Morial Convention Center in New Orleans. The company's presentations will focus on their MCO-010 optogenetic therapy, designed for retinal degenerative diseases.
Nanoscope is developing mutation-agnostic, sight-restoring optogenetic therapies for patients blinded by retinal degenerative diseases. Their MCO-010 therapy has received FDA Fast Track and Orphan Drug designations for both Retinitis Pigmentosa (RP) and Stargardt disease. Following positive end-of-study results from the RESTORE Phase 2b clinical trial for RP, Nanoscope plans to initiate a Biologics License Application (BLA) submission for MCO-010 to treat RP in 2025. Additionally, the company has completed the Phase 2 STARLIGHT trial for MCO-010 in Stargardt patients and intends to initiate a Phase 3 registrational trial in 2025. Preclinical programs also include an asset for Leber Congenital Amaurosis (LCA) in IND-enabling studies.
For patients and families affected by IRDs, these presentations at ASGCT 2025 represent potential progress in the development of new treatment options. The focus on optogenetic therapy, particularly MCO-010, which is mutation-agnostic, means it could potentially benefit a broader range of individuals regardless of their specific genetic mutation. The ongoing clinical trials for RP and Stargardt disease, along with preclinical work in LCA, highlight the breadth of Nanoscope's efforts to address significant unmet needs within the IRD community.
Nanoscope Therapeutics anticipates sharing details about the positive therapeutic benefits observed in Stargardt patients, which were reportedly similar to the vision gains seen in patients with retinitis pigmentosa. The company views this as an exciting time as they prepare MCO-010 for potential commercialization, including the BLA submission.